A GENS-based approach to cardiovascular pharmacology: Impact on metabolism, pharmacokinetics and pharmacodynamics

Flavia Franconi, Ciriaco Carru, Ilaria Spoletini, Walter Malorni, Stefano Vella, Giuseppe Mercuro, Martino Deidda, Giuseppe Rosano

Research output: Contribution to journalArticlepeer-review

Abstract

Pharmacological outcomes depend on many factors, with many of them being sexually dimorphic. Thus, physiological gender/sex (GENS) differences can influence pharmacokinetics, pharmacodynamics and, thus, bioavailability and resulting in efficacy of treatment, meaning GENS differences should be an important consideration in therapeutics. In particular, drug response can change according to different hormonal environments. Therefore, GENS-specific differences have a particular clinical relevance in terms of drug delivery, especially for those substances with a narrow therapeutic margin. Since adverse effects are more frequent among women, safety is a key issue. Overall, the status of women, from a pharmacological point of view, is often different and less studied than that of men and deserves particular attention. Further studies focused on women's responses to drugs are necessary in order to make optimal pharmacotherapeutic decisions.

Original languageEnglish
Pages (from-to)1437-1453
Number of pages17
JournalTherapeutic Delivery
Volume2
Issue number11
DOIs
Publication statusPublished - Nov 2011

ASJC Scopus subject areas

  • Pharmaceutical Science

Fingerprint Dive into the research topics of 'A GENS-based approach to cardiovascular pharmacology: Impact on metabolism, pharmacokinetics and pharmacodynamics'. Together they form a unique fingerprint.

Cite this